valu usd unless otherwis note
shelter storm
view oper excel valid view defens
safe shelter econom uncertainti see
limit covid impact strong oper execut approach
clinic catalyst creat entic stock setup continu
watch sign pipelin de-risk grow posit
strong consist valid view high-qual
defens shelter report beat across top line revenu
vs st bottom line non-gaap ep vs vs st
beat re-affirmed guid revenu non-
maintain guidanc potenti opportunist strateg busi
develop strong balanc sheet cash cash
flow per quarter run-rat support view defens name
larg limit xgeva prolia bone franchis
inventori build tailwind benefit revenu
call saw convers around bite pipelin decis make
discontinu short-half-lif psma bcma bite half-lif extend
version capit expenditur opportunist bd therapeut
platform focus discuss around kra durabl
recent bear argument otezla strong perform
lacklust partial valid channel-stuffing-prior-to-hand-
thesi entic updat model
perform maintain pt
upcom catalyst updat result
solid tumor initi data pivot studi
advanc nsclc may ii data studi
bite molecul iii updat result
bispecif rraml iv data galactic-
hf studi omecamtiv readout navig studi
tezepelumab partner astrazeneca sever uncontrol asthma
vi data studi otezla mild-moder psoriasi
vii pdufa kyproli snda combin darzalex rr
multipl myeloma vii pdufa abp rituxan
biosimilar dec
model chang updat model financi result
slightli reduc revenu estim vs previou
primarili reduc revenu estim aimovig
prolia impact xgeva impact
partial off-set increas revenu estim otezla
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
see moder forward growth follow
otezla acquisit announc await emerg
pipelin aimovig fill shoe ns
matur product eros longer term see
inexpens biotech compani rel basi like
dividend perspect steadi cash flow
despit headwind base busi see
acquisit celg/bmi otezla franchis immedi
accret well-suit add exist
combin enbrel legal win pipelin
enabl majorli grow revenu next year
argu higher re-rat earn multipl
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate assum
trade discount valu forward price-to-earnings basi vs
peer similar growth prospect discount project
revenu legaci product contribut
discount revenu growth product contribut
sh discount risk-adjust revenu pipelin product
contribut discount revenu biosimilar
product contribut net cash contribut
sh result price target support
upsid scenario assum slower-than-
anticip revenu eros base busi
higher-than-expect uptak repatha
downsid scenario assum faster-than-
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
continu page
maintain revenu estim addit reduc expens
sg expens maintain pt sector perform rate
valu dcf basi use wacc termin growth rate
assum trade discount valu forward price-to-earnings basi vs peer similar growth
prospect discount project revenu legaci product contribut
discount revenu growth product contribut discount risk-adjust
revenu pipelin product contribut discount revenu biosimilar
product contribut net cash contribut result price
target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
compani report capit market estim
chang model revenu expens mm expens mm expens mm incom mm incom mm incom mm non-gaap ep exhibit incom statement
compani report capit market estim
incom commerci pipelin product product product cost expens non oper incom ebit non incom tax tax net ep ep ep ep exhibit dcf valuat
compani report capit market estim
compani report capit market estim
dollar mm except per-shar data discount add add effect add termin biotechnolog
